A phase II, randomized, placebo‐controlled, double‐blind, multi‐dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes - Baksi, Arun; Kraydashenko, Oleg; Zalevkaya, Alsu; Stets, Roman; Elliott, Peter; Haddad, Jonathan; Hoffmann, Ethan; Vlasuk, George P.; Jacobson, Eric W. (British journal of clinical pharmacology, 2014)
Keywords: Adult; Aged; Blood Glucose - drug effects; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Enzyme Activation - drug effects; Enzyme Activators - adverse effects; Enzyme Activators - pharmacokinetics; Enzyme Activators - pharmacology; Enzyme Activators - therapeutic use; Female; glucose homeostasis; Heterocyclic Compounds, 2-Ring - adverse effects; Heterocyclic Compounds, 2-Ring - pharmacokinetics; Heterocyclic Compounds, 2-Ring - pharmacology; Heterocyclic Compounds, 2-Ring - therapeutic use; Humans; insulin; Insulin - blood; Male; Metformin - therapeutic use; Middle Aged; Pharmacodynamics; SIRT1; sirtuin; Sirtuin 1 - metabolism; SRT2104; type 2 diabetes mellitus; type 2 diabetes mellitus; SRT2104; glucose homeostasis; insulin; sirtuin; SIRT1